Skip to main content
Critical Care logoLink to Critical Care
. 2013 Mar 19;17(Suppl 2):P345. doi: 10.1186/cc12283

Neuroprotective effect of a new synthetic aspirin-decursinol adduct in a rat model of ischemic stroke

YH Lee 1,, CW Park 1, JH Cho 1, MH Won 1
PMCID: PMC3642797

Introduction

Stroke is a major cause of death. This study investigated the preventative effect of a new synthetic drug on brain function in experimentally induced ischemic stroke.

Methods

Male Sprague-Dawley rats were administered aspirin (ASA), decursinol (DA) or ASA-DA before and after ischemic insults. Brain and neuronal damage were examined by TTC staining, PEP-CT, NeuN immunohistochemistry and F-J B histofluorescence. Gliosis was also observed by GFAP and iba-1 immunohistochemistry.

Results

Pretreatment with 20 mg/kg, but not 10 mg/kg, of ASA-DA protected against ischemic neuronal death and damage, and its neuroprotective effect was much more pronounced than that of ASA or DA alone. In addition, treatment with 20 mg/kg ASA-DA reduced the ischemia-induced activation of astrocytes and microglia.

Conclusion

Our findings indicate that ASA-DA, a new synthetic drug, prevents against transient focal cerebral ischemia, which provides a resource for the development of its clinical application for stroke.


Articles from Critical Care are provided here courtesy of BMC

RESOURCES